USC EdTech Accelerator collaborates with Intel

Focus will be on developing efficacious AI solutions that improve learning outcomes with an emphasis on supporting marginalized communities.

2024-06-12

(Press-News.org) USC Rossier Education Technology Accelerator (USC EdTech Accelerator) announced a unique collaboration with Intel Corporation focused on supporting the use of technology for learning with a particular emphasis on supporting marginalized communities and AI.

The Partnership

The USC EdTech collaboration with Intel will provide free educational and technical assistance to learning-focused start-ups to increase the likelihood that they design viable, efficacious and scalable AI-enhanced solutions for learners. “We believe Intel’s technical expertise and industry insights will be enormously valuable to companies in our program, particularly those companies started by non-technical founders,” said Doug Lynch, senior fellow at USC Rossier School of Education. “We are thrilled that Intel sees value in supporting founders committed to educational equity and we believe our partnership will provide our founders with the necessary knowledge and tools to help them design and utilize AI in their products to increase efficacy and impact.”

Among other things, Intel leaders will hold seminars on specific industry and technology issues and provide training and individualized technical and business mentoring to companies currently in the USC EdTech Accelerator as well as to alumni of the program. “We look forward to working with the USC EdTech Accelerator to tailor a program to meet its cohorts’ needs,” said Michael Campbell, general manager of Intel’s Education Division. “We have been very impressed with the diversity of founders and quality of the technology solutions. This collaboration will build on our mission to increase educational access and improve educational outcomes for all learners through technology, inclusion and digital readiness.”

“We continue to be thankful for USC’s on-going support of our work and look forward to learning from Intel,” said Valencia Belle, founder and CEO of Schools, Inc., who is an alumnus of the USC program. “It will help enhance what we do for kids.”

About the USC EdTech Accelerator:

USC EdTech Accelerator offers free, virtual programming to nurture and accelerate the growth of start-ups offering efficacious solutions that improve access and educational outcomes in all education markets: K–12, higher education and corporate learning. Companies in the program are located all over the world and as a community have touched some nine million learners and raised in excess of $100 million. It is an incredibly inclusive program with over 80% of founders identifying either as women or people of color.

END

ELSE PRESS RELEASES FROM THIS DATE:

What is the neural mechanism behind helping someone at your own cost?

2024-06-12

Using a unique setup, researchers from the Social Brain Lab at the Netherlands Institute for Neuroscience have researched the neural mechanism behind a universal dilemma: deciding whether to help someone else even when it involves a personal sacrifice. We often have opportunities to give up something we care about to help others. What brain mechanisms help us make those decisions, and why do some people help more than others? Over the years, philosophers and scientists have suggested that the extent to which a person empathizes with the distress of others influences their willingness to help. To explore this hypothesis experimentally, Kalliopi ...

Can we withdraw treatment in post-menopausal osteoporosis?

2024-06-12

Osteoporosis is characterised by low bone mineral density and bone fragility.5 During menopause, falling oestrogen levels impair normal bone turnover, with an average reduction in bone mineral density of 10%.5 This is compounded by the age-related bone loss that occurs in both men and women. With an ageing population, post-menopausal osteoporosis represents a growing health problem. These new data are from a case-control cohort study of over 128,000 women included in the French national claim database. The main aim was to estimate the incidence of long-term discontinuation of bisphosphonates – ...

Vexas: towards molecular and phenotypic characterization

2024-06-12

VEXAS is characterised by predominantly rheumatic and haematologic systemic involvement, and caused by somatic mutation in UBA1 – a gene encoding ubiquitin-activating enzyme 1,1,2 which is necessary for a post-translation modification that affects protein functions ranging from degradation to subcellular localisation and kinase activation.3 The syndrome was first described in 2020, but diagnosis can be challenging as the symptoms overlap with many other inflammatory conditions.1 Hot on the heels of this recent discovery, research is underway to better understand pathogenesis, clinical features, and potential treatment options.1 To support this, ...

Location, location, location – does it matter in psoriatic arthritis?

2024-06-12

Arthritis affects various joints differently, despite systemic inflammatory cues.2 In people with rheumatoid arthritis, transcriptomic variances identified in synovial fibroblasts from various joint sites have been shown to translate into joint-specific phenotypes with distinct characteristics and responsiveness to cytokines.2,3 These findings suggest that different joints may potentially respond variably to specific immunosuppressive treatments. To expand on this, Ciurea and colleagues set out to investigate whether joints at different anatomical locations in people with PsA might respond differently to treatment with a tumour necrosis ...

Stopping the march

2024-06-12

The estimated prevalence of psoriatic arthritis (PsA) in people with psoriasis ranges widely –between 6% and 42% – but in most cases, skin symptoms precede PsA, thus making skin psoriasis a model for pre-PsA.2 Assuming that there are shared pathways in the pathogenesis, it is possible that stringent treatment of moderate-to-severe psoriasis could reduce progression to clinically overt PsA.3,4 Biologic treatments are effective at controlling psoriasis, but there are no conclusive data that these treatments help prevent people from developing PsA. Several risk factors for transition have previously been identified by a EULAR taskforce.5 ...

Predicting response in treatment-naïve RA

2024-06-12

The synovial tissue inflammation seen in RA shows high degree of heterogeneity – which may be a factor in people’s variable response to treatments. We also know that distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis.1 The potential of high-throughput analyses has been shown, and these technologies can help dissect disease heterogeneity and identify novel biomarkers that could be used in prognosis.2 To explore this further, 373 treatment-naïve RA patients were enrolled and given an ultrasound-guided synovial tissue biopsy. The synovitis degree and synovial pathotype was then determined for ...

Testing the systemic score for Still’s disease

2024-06-12

A multi-centre, observational, prospective study was designed to evaluate the clinical usefulness of the systemic score in predicting life-threatening evolution – defined as the development of macrophage activation syndrome (MAS) and/or mortality. The intention was also to derive a more aggressive clinical patient subset. To achieve this, Ruscitti and colleagues collected data from 597 patients taking part in the GIRRCS (Gruppo Italiano Di Ricerca in Reumatologia Clinica e Sperimentale) AOSD-study ...

Early RA: Disease trajectories and pain

2024-06-12

The 2024 EULAR congress in Vienna included a clinical abstract session focusing on pain and prognosis in RA, where two groups presented their research into ways to characterise early RA. The first looked at dissecting early RA patient trajectories through time-independent disease state patterns of inflammation in blood or joints. Presenting the work, Nils Steinz said “Previous studies have identified smooth time trajectories of rapid, slow, or no progression of disease activity, assessed through DAS28. In real life, we observe more chaotic disease evolvements – and particularly the detours could ...

Testing the thresholds

2024-06-12

However, this recommendation is not always followed in practice. This could be because the ASDAS was developed for research, and it is not known how well it performs in daily practice. Possibly, the cut-off of 2.1 as currently endorsed may be too strict in an everyday setting. To address this, Webers and colleagues set out to investigate which ASDAS cut-off values correspond best with treatment intensification in practice. Data were taken from a prospective multi-centre registry for SpA, and treatment ...

Ingestible microbiome sampling pill technology advances

2024-06-12

Significant progress has been made at Tufts University School of Engineering in the development of a small device, about the size of a vitamin pill, that can be swallowed and passed through the gastrointestinal tract to sample the full inventory of microorganisms in an individual’s gastro-intestinal tract. This device has the potential to advance research on the relationship between resident bacteria and a wide range of health conditions. It could also serve as a diagnostic tool for adjusting the microbiome or administering drugs to treat those conditions. The device has completed ...

USC EdTech Accelerator collaborates with Intel

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: